N of 1 Data Sharing: The Impact of Data Sharing within the Hematology–Oncology Drug Products Division of the US FDA

Ross, 2019, Sharing clinical trial data: lessons from the YODA Project, STAT Beaver, 2018, Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis, Lancet Oncol., 19, 229, 10.1016/S1470-2045(17)30846-X Wissing, 2014, Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013, Cancer, 120, 3025, 10.1002/cncr.28809 Pulte, 2018, Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications, Blood Adv., 2, 116, 10.1182/bloodadvances.2017010512 Jin, 2017, Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015, J. Clin. Oncol., 35, 3745, 10.1200/JCO.2017.73.4186 Basch, 2014, Pain palliation measurement in cancer clinical trials: The US Food and Drug Administration perspective, Cancer, 120, 761, 10.1002/cncr.28470 Doshi, 2017, The wider role of regulatory scientists, BMJ, 357 Walport, 2011, Sharing research data to improve public health, Lancet, 377, 537, 10.1016/S0140-6736(10)62234-9